MCD
MCID: KPS004
MIFTS: 67

Kaposi Sarcoma (MCD) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Blood diseases, Neuronal diseases

Aliases & Classifications for Kaposi Sarcoma

Aliases & Descriptions for Kaposi Sarcoma:

Name: Kaposi Sarcoma 54 12 50 56 52 14 69
Kaposi's Sarcoma 12 50 41 14
Angiofollicular Ganglionic Hyperplasia 56 69
Kaposi Sarcoma, Susceptibility to 54 13
Kaposi's Sarcoma of Soft Tissue 12 69
Kaposi's Sarcoma of Palate 12 69
Kaposi's Sarcoma of Lung 12 69
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
African Lymphadenopathic Kaposi's Sarcoma 12
Multicentric Giant Lymph Node Hyperplasia 56
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Lymphadenopathic Kaposi's Sarcoma 12
Angiofollicular Lymph Hyperplasia 56
Multi-Centric Castleman's Disease 69
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 50
Non-Aids-Related Kaposi Sarcoma 69
Multicentric Castleman Disease 56
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 50
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 50
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 69
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 50
Castleman Disease 56
Sarcoma, Kaposi 42
Hhv8 50
Kshv 50
Mcd 56

Characteristics:

Orphanet epidemiological data:

56
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

HPO:

32
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Kaposi Sarcoma

NIH Rare Diseases : 50 kaposi sarcoma (ks) is a cancer that develops from the cells that line lymph or blood vessels. it usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). the abnormal cells of kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. these lesions may look bad, but they usually cause no symptoms. however, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. kaposi sarcoma is caused by infection with a virus called the kaposi sarcoma associated herpesvirus (kshv), also known as human herpesvirus 8 (hhv8). kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-saharan indigenous africans), iatrogenic (associated with immunosuppressive drug therapy) and aids-associated (epidemic ks). options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy (immunotherapy). the main aim is to restore immunity. last updated: 2/4/2016

MalaCards based summary : Kaposi Sarcoma, also known as kaposi's sarcoma, is related to angiofollicular lymph hyperplasia and endemic kaposi sarcoma, and has symptoms including fatigue, fever and diarrhea. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Doxil and Intron A have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and skin, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results_in_formation_of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

OMIM : 54 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with... (148000) more...

MedlinePlus : 41 kaposi's sarcoma (ks) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. these patches, or lesions, are usually red or purple. they are made of cancer cells, blood vessels, and blood cells. ks is caused by infection with human herpesvirus-8 (hhv-8). most people infected with hhv-8 don't get ks. it usually happens in people with weak immune systems, due to hiv/aids, drugs taken after an organ transplant, or another disease older men of jewish or mediterranean descent young men in africa the skin lesions may not cause symptoms. but they can spread to other parts of the body, especially in people with hiv/aids. if they spread to the digestive tract or lungs, they can cause bleeding. lesions on the lungs can also make it hard to breathe. treatment depends on where the lesions are and how bad they are. options include radiation therapy, surgery, chemotherapy, and biologic therapy. people with hiv/aids also take hiv/aids medicines. nih: national cancer institute

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
id Related Disease Score Top Affiliating Genes
1 angiofollicular lymph hyperplasia 12.2
2 endemic kaposi sarcoma 12.2
3 colon kaposi sarcoma 12.0
4 human herpesvirus 8 11.8
5 immunodeficiency 16 11.7
6 unicentric castleman disease 11.2
7 rectum kaposi's sarcoma 11.0
8 sarcoma 10.9
9 bipolar i disorder 10.3 FGF2 IL6 VEGFA
10 vitreoretinopathy, neovascular inflammatory 10.3 IL6 IL6R IL6ST
11 lymphoma 10.3
12 pyriform sinus cancer 10.3 FGF2 IL6 VEGFA
13 benign idiopathic neonatal seizures 10.3 FGF2 KDR VEGFA
14 vesiculobullous skin disease 10.3 FLT4 KDR VEGFA
15 thyroid angiosarcoma 10.3 CD34 VEGFA
16 urinary bladder posterior wall cancer 10.3 FGF2 IL6 VEGFA
17 castleman disease 10.3
18 multicentric castleman disease 10.3
19 neurilemmoma of the pleura 10.3 FGF2 KDR VEGFA
20 spinocerebellar ataxia 25 10.3 IL6 KDR VEGFA
21 factitious disorder 10.3 FLT4 KDR VEGFA
22 congenital disorder of glycosylation, type iq 10.3 FGF2 IFNA1 IFNA2
23 vulvitis 10.3 IL6 KDR VEGFA
24 subdural empyema 10.3 FGF2 KDR VEGFA
25 keratosis follicularis spinulosa decalvans 10.3 CD34 FLT4 KDR
26 hypomelanosis of ito 10.3 FLT4 IFNA2
27 circumscribed cutaneous aplasia of the vertex 10.3 CD34 IFNA1 IFNA2
28 oppositional defiant disorder 10.3 FGF2 IL6 KDR VEGFA
29 pilomyxoid astrocytoma 10.3 FLT4 IFNA2
30 anterograde amnesia 10.3 FGF2 IL6 VEGFA
31 human granulocytic anaplasmosis 10.3 FLT4 KDR VEGFA
32 orofaciodigital syndrome 13 10.3 FLT4 PDPN
33 malignant glioma 10.2 IFNA1 IFNA2
34 craniosynostosis, type 1 10.2 IL6 VEGFA
35 grade iii astrocytoma 10.2 FGF2 IL6 KDR VEGFA
36 anterior foramen magnum meningioma 10.2 CD34 IFNA1 IFNA2 IL6
37 gestational choriocarcinoma 10.2 CD34 FGF2 VEGFA
38 neuropathy, hereditary sensory, type ib 10.2 FGF2 KDR VEGFA
39 familial acute necrotizing encephalopathy 10.2 IFNA1 IFNA2 PDPN
40 primary effusion lymphoma 10.2
41 phencyclidine abuse 10.2 CD34 FLT4 PDPN
42 citrullinemia, type ii, neonatal-onset 10.2 FGF2 KDR VEGFA
43 uterine benign neoplasm 10.2 CD34 FGF2 PDPN
44 conventional leiomyosarcoma 10.2 CD34 FGF2 PDPN
45 ceruminoma 10.2 IFNA1 IFNA2
46 acquired immunodeficiency syndrome 10.2
47 hyperpituitarism 10.2 CD34 FGF2 PDPN
48 senile cataract 10.2 IFNA1 IFNA2 IL6
49 lymphoma, large-cell, immunoblastic 10.2 FLT4 KDR PDPN
50 cutis laxa, autosomal recessive, type ib 10.2 CD34 IFNA1 IL6 IL6R VEGFA

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Symptoms by clinical synopsis from OMIM:

148000

Clinical features from OMIM:

148000

Human phenotypes related to Kaposi Sarcoma:

56 32 (show all 28)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 56 32 Occasional (29-5%) HP:0012378
2 fever 56 32 Occasional (29-5%) HP:0001945
3 diarrhea 56 32 Occasional (29-5%) HP:0002014
4 immunodeficiency 56 32 Frequent (79-30%) HP:0002721
5 weight loss 56 32 Occasional (29-5%) HP:0001824
6 lymphedema 56 32 Occasional (29-5%) HP:0001004
7 abnormality of the spleen 56 32 Frequent (79-30%) HP:0001743
8 neoplasm of the skin 56 32 Very frequent (99-80%) HP:0008069
9 skin rash 56 32 Occasional (29-5%) HP:0000988
10 abnormality of lung morphology 56 32 Occasional (29-5%) HP:0002088
11 venous insufficiency 56 32 Occasional (29-5%) HP:0005293
12 hypermelanotic macule 56 32 Very frequent (99-80%) HP:0001034
13 papule 56 32 Frequent (79-30%) HP:0200034
14 abnormality of the gastrointestinal tract 56 32 Frequent (79-30%) HP:0011024
15 abnormality of the liver 56 32 Occasional (29-5%) HP:0001392
16 encephalopathy 56 32 Frequent (79-30%) HP:0001298
17 abnormality of the lower limb 56 32 Very frequent (99-80%) HP:0002814
18 abnormality of the retina 56 32 Frequent (79-30%) HP:0000479
19 skin nodule 56 32 Frequent (79-30%) HP:0200036
20 skin plaque 56 32 Occasional (29-5%) HP:0200035
21 hemangioma 56 32 Frequent (79-30%) HP:0001028
22 generalized lymphadenopathy 56 32 Frequent (79-30%) HP:0008940
23 susceptibility to herpesvirus 56 32 Obligate (100%) HP:0005353
24 lymphoproliferative disorder 56 32 Frequent (79-30%) HP:0005523
25 edema 32 HP:0000969
26 macule 56 Very frequent (99-80%)
27 neoplasm 32 HP:0002664
28 neoplasm by anatomical site 56 Occasional (29-5%)

UMLS symptoms related to Kaposi Sarcoma:


exanthema, pruritus, fever

MGI Mouse Phenotypes related to Kaposi Sarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.15 IL6 IL6R IL6ST KDR OSM PDPN
2 cellular MP:0005384 10.14 CD34 CDK6 FGF2 FGF4 IL6 IL6R
3 homeostasis/metabolism MP:0005376 10.1 FGF2 FLT4 IL6 IL6R IL6ST KDR
4 immune system MP:0005387 10.07 CCR8 CD34 CDK6 FLT4 IL6 IL6R
5 integument MP:0010771 9.9 PDPN SLC7A11 STIM1 VEGFA CD34 FGF5
6 liver/biliary system MP:0005370 9.5 CDK6 FLT4 IL6 IL6R IL6ST KDR
7 neoplasm MP:0002006 9.23 CD34 CDK6 FGF2 IL6 IL6R IL6ST

Drugs & Therapeutics for Kaposi Sarcoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
3
Taxol 17 46 PACLITAXEL Bristol-Myers Squibb Approved August 1997

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
5
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
6
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
7
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
10
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
11
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
12
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
13
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
14
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
15 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
17 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
19 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
22 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3
23 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
24 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
25 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
26 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
27 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
28 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
29 Ganciclovir triphosphate Phase 4,Phase 2
30
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
31
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
32
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 65140 441300
33
Zidovudine Approved Phase 2, Phase 3, Phase 1 30516-87-1 35370
34
Daunorubicin Approved Phase 3,Phase 1 20830-81-3 30323
35
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
36
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
37 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
39 Antimitotic Agents Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Analgesics Phase 3,Phase 2,Phase 1
43 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
44 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
45 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1,Phase 2
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1
47 Cyclooxygenase 2 Inhibitors Phase 3
48 Cyclooxygenase Inhibitors Phase 3
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Albumin-Bound Paclitaxel Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 163)
id Name Status NCT ID Phase
1 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4
2 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4
3 Organ Transplant Infection Prevention and Detection Project Completed NCT00177801 Phase 4
4 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4
5 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3
6 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3
7 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3
8 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3
9 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3
10 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3
11 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3
12 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3
13 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3
14 A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00000994 Phase 3
15 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3
16 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Recruiting NCT01435018 Phase 3
17 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Active, not recruiting NCT01352117 Phase 3
18 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Active, not recruiting NCT01924286 Phase 3
19 A Study of Selumetinib in Patients With Kaposi's Sarcoma Unknown status NCT01752569 Phase 1, Phase 2
20 Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma Unknown status NCT00003419 Phase 2
21 Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer Unknown status NCT00622466 Phase 2
22 Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma Completed NCT01067690 Phase 2
23 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity Completed NCT01296815 Phase 2
24 Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir Completed NCT00362310 Phase 2
25 Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00064142 Phase 2
26 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients Completed NCT00055237 Phase 2
27 Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2
28 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2
29 BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2
30 Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma Completed NCT00295984 Phase 2
31 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00090987 Phase 2
32 SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00005042 Phase 2
33 Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma Completed NCT00019123 Phase 2
34 Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00003008 Phase 2
35 Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection Completed NCT00019240 Phase 2
36 Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00020449 Phase 2
37 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT Completed NCT02201420 Phase 2
38 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma Completed NCT02029430 Phase 2
39 Suppression of Oral HHV8 Shedding With Valganciclovir Completed NCT00194467 Phase 2
40 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002188 Phase 2
41 A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Completed NCT00002131 Phase 2
42 A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002212 Phase 2
43 The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Completed NCT00002366 Phase 2
44 Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed NCT00002259 Phase 2
45 SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment Completed NCT00005931 Phase 2
46 The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma Completed NCT00001114 Phase 2
47 Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Completed NCT00002167 Phase 2
48 A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma Completed NCT00002314 Phase 2
49 A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00000996 Phase 2
50 Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals Completed NCT00002189 Phase 2

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Anatomical Context for Kaposi Sarcoma

MalaCards organs/tissues related to Kaposi Sarcoma:

39
Lung, Lymph Node, Skin, Prostate, Liver, Heart, T Cells

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 356)
id Title Authors Year
1
Acral pseudolymphomatous angiokeratoma of children with rainbow pattern: A mimicker of Kaposi sarcoma. ( 28087020 )
2017
2
Is acquired arterial-venous fistula related to Kaposi sarcoma? ( 28214029 )
2017
3
Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. ( 28424322 )
2017
4
RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. ( 28046107 )
2017
5
Recombinant parvoviruses armed to deliver CXCL4L1 and CXCL10 are impaired in their antiangiogenic and antitumoral effects in a Kaposi sarcoma tumor model due to the chemokines' interference with the virus cycle. ( 28042949 )
2017
6
Kaposi sarcoma, oral malformations, mitral dysplasia, and scoliosis associated with 7q34-q36.3 heterozygous terminal deletion. ( 28488400 )
2017
7
Hepatic Kaposi sarcoma: A case report and review of the literature. ( 28217255 )
2017
8
Kaposi Sarcoma in a patient treated with Ruxolitinib. ( 28419187 )
2017
9
Kaposi Sarcoma and Lung Transplant: Two Case Reports. ( 28501344 )
2017
10
Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. ( 28430817 )
2017
11
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. ( 28394855 )
2017
12
Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study. ( 28157730 )
2017
13
Pulmonary Kaposi Sarcoma with Osseous Metastases in an Human Immunodeficiency Virus (HIV) Patient: A Remarkable Response to Highly Active Antiretroviral Therapy. ( 28216610 )
2017
14
Classic Kaposi sarcoma in an HIV-negative Han Chinese man: a case report. ( 28329475 )
2017
15
Topical diphencyprone for Kaposi sarcoma. ( 28133860 )
2017
16
BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV. ( 28404899 )
2017
17
mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi Sarcoma. ( 28506734 )
2017
18
Increasing Numbers of New Kaposi Sarcoma Diagnoses in HIV-Infected Children and Adolescents Despite the Wide Availability of Antiretroviral Therapy in Malawi. ( 28077522 )
2017
19
Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. ( 27986137 )
2017
20
Comparison of Kaposi sarcoma risk in HIV-positive adults across five continents: a multiregional multicohort study. ( 28531260 )
2017
21
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. ( 28341759 )
2017
22
Pulmonary Kaposi sarcoma presenting as complete lung consolidation. ( 28331023 )
2017
23
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. ( 27770395 )
2017
24
Lymphangioma-like classic Kaposi sarcoma. ( 28188608 )
2017
25
Ultraviolet Radiation and Kaposi Sarcoma Incidence in a Nationwide US Cohort of HIV-Infected Men. ( 28040691 )
2017
26
Acquired Immune Deficiency Syndrome-Associated Kaposi Sarcoma in a Child Presenting as a Solitary Plantar Hyperkeratotic Plaque. ( 28288525 )
2017
27
A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura. ( 27885868 )
2017
28
Diagnosis and Treatment of Kaposi Sarcoma. ( 28324233 )
2017
29
Kaposi sarcoma: an unusual cause of gastrointestinal bleeding. ( 26896679 )
2016
30
Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. ( 27578823 )
2016
31
Asymptomatic Pulmonary Allograft Kaposi Sarcoma: A Case Report. ( 26767437 )
2016
32
A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma. ( 26823008 )
2016
33
Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study. ( 27082863 )
2016
34
Pulmonary Kaposi Sarcoma: An Uncommon Cause of Respiratory Failure in the Era of Highly Active Antiretroviral Therapy-Case Report and Review of the Literature. ( 27872774 )
2016
35
Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. ( 26811480 )
2016
36
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. ( 27662664 )
2016
37
Hepatic Kaposi Sarcoma Revisited: An Important but Less Commonly Seen Neoplasm in Patients With Acquired Immunodeficiency Syndrome. ( 27984514 )
2016
38
Asymmetric relapse of an HIV-associated Kaposi sarcoma. ( 27832310 )
2016
39
Severe Kaposi Sarcoma in an Urban Public Hospital. ( 28019110 )
2016
40
Primary effusion lymphoma and concurrent progressive Kaposi sarcoma associated with elevated interleukin-6. ( 28092896 )
2016
41
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. ( 27584730 )
2016
42
Kaposi sarcoma herpesvirus-associated disorders and related diseases. ( 27662501 )
2016
43
Genotypic distribution of HHV-8 in AIDS individuals without and with Kaposi sarcoma: Is genotype B associated with better prognosis of AIDS-KS? ( 27902590 )
2016
44
Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function. ( 27893813 )
2016
45
Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma. ( 27996149 )
2016
46
Non-AIDS Kaposi sarcoma in the external ear. ( 27370401 )
2016
47
Kaposi Sarcoma among HIV Infected Patients in Lagos University Teaching Hospital, Nigeria: A 14-Year Retrospective Clinicopathological Study. ( 27034839 )
2016
48
Mapping the Epidemiology of Kaposi Sarcoma and Non-Hodgkin Lymphoma Among Children in Sub-Saharan Africa: A Review. ( 27082516 )
2016
49
Kaposi Sarcoma of the Plantar Surface. ( 27432041 )
2016
50
Identification of Kaposi Sarcoma Herpesvirus (KSHV) vIRF1 Protein as a Novel Interaction Partner of Human Deubiquitinase USP7. ( 26786098 )
2016

Variations for Kaposi Sarcoma

Cosmic variations for Kaposi Sarcoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 65
2 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 65
3 COSM521 KRAS biliary tract,gallbladder,other,hyperplasia c.35G>A p.G12D 6
4 COSM517 KRAS biliary tract,gallbladder,other,hyperplasia c.34G>A p.G12S 6

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 43)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 CD34 FGF2 FGF4 FGF5 IFNA1 IFNA2
2
Show member pathways
13.83 CCR8 CDK6 FGF2 FGF4 FGF5 FLT4
3
Show member pathways
13.63 CCR8 FLT4 IFNA1 IFNA2 IL6 IL6R
4
Show member pathways
13.47 FGF2 FGF4 FGF5 FLT4 IFNA1 IFNA2
5
Show member pathways
13.36 CCR8 FGF2 FGF4 FGF5 FLT4 IL6
6
Show member pathways
13.25 FGF2 FGF4 FGF5 FLT4 IL6 KDR
7
Show member pathways
13.21 CCR8 FGF2 FGF4 FGF5 FLT4 IL6
8
Show member pathways
13.18 FGF2 FGF4 FGF5 IFNA1 IFNA2 IL6
9
Show member pathways
13.03 FGF2 FGF4 FGF5 FLT4 IL6 KDR
10
Show member pathways
13.02 FGF2 FGF4 FGF5 FLT4 IL6 KDR
11
Show member pathways
12.77 CDK6 FGF2 FGF4 FGF5 FLT4 IL6
12
Show member pathways
12.71 FGF2 FGF4 FGF5 FLT4 KDR VEGFA
13
Show member pathways
12.66 FGF2 FGF4 FGF5 FLT4 IL6 KDR
14 12.62 CDK6 FGF2 FGF4 FGF5 IL6 VEGFA
15
Show member pathways
12.29 FGF2 FGF4 FGF5 FLT4 KDR VEGFA
16
Show member pathways
12.04 IFNA1 IFNA2 IL6 IL6R IL6ST OSM
17 11.98 FGF2 FGF4 IL6 KDR VEGFA
18 11.94 CDK6 FGF2 FGF4 FGF5 FLT4 IFNA1
19 11.87 CD34 FGF2 FGF4 IL6
20 11.86 IL6 IL6R VEGFA
21 11.86 FGF2 IL6 IL6R OSM VEGFA
22 11.85 CD34 IL6 IL6R
23
Show member pathways
11.83 IL6 IL6R IL6ST
24
Show member pathways
11.82 FLT4 KDR VEGFA
25
Show member pathways
11.81 FGF2 FGF4 FGF5
26 11.79 FGF2 FLT4 KDR
27
Show member pathways
11.78 IL6 IL6R IL6ST
28 11.75 FGF2 FGF4 VEGFA
29 11.72 CD34 IFNA2 IL6
30 11.62 FGF2 FGF4 FGF5
31
Show member pathways
11.58 FGF2 FGF4 FGF5
32
Show member pathways
11.54 IL6 IL6R IL6ST OSM
33 11.52 IL6 IL6R VEGFA
34 11.5 FGF2 KDR VEGFA
35 11.47 FGF2 KDR VEGFA
36 11.42 IFNA1 IFNA2 IL6
37
Show member pathways
11.41 IL6 IL6R IL6ST
38 11.38 IFNA1 IFNA2 IL6 IL6R IL6ST
39 11.3 IL6 IL6R IL6ST
40 11.13 FGF2 KDR VEGFA
41 11.03 FGF2 FGF4 IL6 IL6R VEGFA
42 10.98 IL6ST OSM VEGFA
43
Show member pathways
10.89 FLT4 KDR VEGFA

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 CD34 FGF2 FGF4 FGF5 FLT4 IFNA1
2 external side of plasma membrane GO:0009897 9.56 CD34 IL6 IL6ST PDPN
3 ciliary neurotrophic factor receptor complex GO:0070110 9.16 IL6R IL6ST
4 interleukin-6 receptor complex GO:0005896 8.8 IL6 IL6R IL6ST

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 46)
id Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.98 FGF2 FLT4 KDR VEGFA
2 positive regulation of protein phosphorylation GO:0001934 9.92 FGF4 FLT4 KDR VEGFA
3 regulation of cell shape GO:0008360 9.89 IL6 KDR PDPN VEGFA
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 FGF2 FGF4 FLT4 IL6 KDR
5 phosphatidylinositol phosphorylation GO:0046854 9.87 FGF2 FGF4 FGF5
6 fibroblast growth factor receptor signaling pathway GO:0008543 9.86 FGF2 FGF4 FGF5
7 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.86 FGF2 FGF4 FGF5
8 positive regulation of angiogenesis GO:0045766 9.86 CD34 FGF2 KDR VEGFA
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 IL6 OSM VEGFA
10 peptidyl-tyrosine phosphorylation GO:0018108 9.85 FGF2 FGF4 FGF5 FLT4 KDR
11 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.84 FLT4 KDR VEGFA
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 IL6 IL6R OSM VEGFA
13 response to cytokine GO:0034097 9.83 IL6 IL6R IL6ST
14 humoral immune response GO:0006959 9.82 IFNA1 IFNA2 IL6
15 positive regulation of osteoblast differentiation GO:0045669 9.82 IL6 IL6R IL6ST
16 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.81 FGF2 FGF4 FGF5
17 positive regulation of MAPK cascade GO:0043410 9.81 FLT4 IL6 KDR OSM
18 cytokine-mediated signaling pathway GO:0019221 9.8 IFNA1 IFNA2 IL6 IL6R IL6ST
19 positive regulation of endothelial cell proliferation GO:0001938 9.78 FGF2 FLT4 KDR VEGFA
20 positive regulation of endothelial cell migration GO:0010595 9.77 FLT4 KDR VEGFA
21 positive regulation of leukocyte chemotaxis GO:0002690 9.7 IL6 IL6R
22 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.7 FLT4 KDR VEGFA
23 lymphangiogenesis GO:0001946 9.69 FLT4 PDPN
24 positive regulation of positive chemotaxis GO:0050927 9.69 KDR VEGFA
25 negative regulation of hormone secretion GO:0046888 9.68 IL6 OSM
26 positive regulation of cellular component movement GO:0051272 9.67 PDPN VEGFA
27 positive regulation of vasculogenesis GO:2001214 9.67 CD34 KDR
28 stem cell proliferation GO:0072089 9.66 CD34 FGF2
29 positive regulation of protein kinase C signaling GO:0090037 9.66 FLT4 VEGFA
30 vascular endothelial growth factor signaling pathway GO:0038084 9.65 FLT4 KDR
31 positive regulation of cell division GO:0051781 9.65 FGF2 FGF4 FGF5 OSM VEGFA
32 endothelium development GO:0003158 9.64 CD34 KDR
33 chondroblast differentiation GO:0060591 9.62 FGF2 FGF4
34 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.61 KDR VEGFA
35 ciliary neurotrophic factor-mediated signaling pathway GO:0070120 9.61 IL6R IL6ST
36 cell migration involved in sprouting angiogenesis GO:0002042 9.61 FGF2 KDR VEGFA
37 oncostatin-M-mediated signaling pathway GO:0038165 9.58 IL6ST OSM
38 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.57 FGF2 FGF4
39 hepatic immune response GO:0002384 9.55 IL6 IL6R
40 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.55 IFNA2 IL6 IL6R IL6ST OSM
41 positive regulation of acute inflammatory response GO:0002675 9.54 IL6 IL6ST OSM
42 interleukin-6-mediated signaling pathway GO:0070102 9.5 IL6 IL6R IL6ST
43 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 IFNA2 IL6 IL6R IL6ST OSM VEGFA
44 positive regulation of cell proliferation GO:0008284 9.32 FGF2 FGF4 FGF5 FLT4 IL6 IL6R
45 negative regulation of apoptotic process GO:0043066 10.05 FGF4 FLT4 IL6 IL6ST KDR VEGFA
46 positive regulation of gene expression GO:0010628 10.03 CD34 CDK6 FGF4 IL6 VEGFA

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.69 FGF2 FGF4 FGF5
2 1-phosphatidylinositol-3-kinase activity GO:0016303 9.65 FGF2 FGF4 FGF5
3 protein tyrosine kinase activity GO:0004713 9.65 FGF2 FGF4 FGF5 FLT4 KDR
4 growth factor binding GO:0019838 9.63 FLT4 IL6ST KDR
5 fibroblast growth factor receptor binding GO:0005104 9.58 FGF2 FGF4 FGF5
6 vascular endothelial growth factor-activated receptor activity GO:0005021 9.49 FLT4 KDR
7 ciliary neurotrophic factor receptor activity GO:0004897 9.43 IL6R IL6ST
8 cytokine activity GO:0005125 9.43 FGF2 IFNA1 IFNA2 IL6 OSM VEGFA
9 interleukin-6 binding GO:0019981 9.37 IL6R IL6ST
10 interleukin-6 receptor binding GO:0005138 9.33 IL6 IL6R IL6ST
11 interleukin-6 receptor activity GO:0004915 9.32 IL6R IL6ST
12 growth factor activity GO:0008083 9.1 FGF2 FGF4 FGF5 IL6 OSM VEGFA

Sources for Kaposi Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....